30 September 2022Regulatory Scandion Oncology announce topline results from part 2 of the CORIST phase II trial Download Presentation Webcast Workbook
31 August 2022Regulatory Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology Download Presentation Webcast Workbook
30 August 2022Regulatory Scandion Oncology announce change to its Executive Management Download Presentation Webcast Workbook
19 August 2022Regulatory Scandion Oncology receives approvals for next parts of the CORIST trial Download Presentation Webcast Workbook
18 August 2022Regulatory Invitation to Scandion Oncology webcast and conference call August 25, 2022 Download Presentation Webcast Workbook
17 August 2022Regulatory Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101 Download Presentation Webcast Workbook
8 August 2022Regulatory Scandion Oncology announces share purchase by Board of Directors Download Presentation Webcast Workbook
26 July 2022Regulatory Scandion Oncology’s rights issue registered with the Danish Business Authority Download Presentation Webcast Workbook
4 July 2022Regulatory Scandion Oncology announces final outcome of its rights issue Download Presentation Webcast Workbook
1 July 2022Regulatory Scandion Oncology announces preliminary outcome of its rights issue Download Presentation Webcast Workbook
16 June 2022Regulatory Subscription period in Scandion Oncology Rights Issue of up to approximately SEK 93.7 million commences Download Presentation Webcast Workbook
15 June 2022Regulatory Scandion Oncology publishes prospectus in connection with the rights issue of up to approximately SEK 93.7 million Download Presentation Webcast Workbook